ArticleMacromolecular bioscience2026
Triblock Polyampholyte-Based Nanovesicles for Targeted Spleen Delivery.
Article in Macromolecular bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Triblock Polyampholyte-Based Nanovesicles for Targeted Spleen Delivery.Macromolecular bioscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Polymeric vesicles are a promising platform for targeted drug delivery. In this study, nanovesicles are developed using triblock polyampholytes composed of neutral poly(ethylene glycol), cationic poly(L-lysine), and anionic poly(α,β-aspartic acid) segments (PEG-PLys-PAsp) poly(aspartate) segments. By controlling the polymerization degree of these cationic and anionic segments, narrowly distributed nanovesicles are successfully assembled with a hydrodynamic diameter of ≈140 nm. The membrane thickness of the nanovesicles is around 15 nm, corresponding to a uniform polyion complex layer. Cross-linking the membrane of the nanovesicles via amide bonds enhance their stability in physiological salt and temperature conditions. In vivo, the cross-linked nanovesicles exhibit prolonged blood circulation and selective accumulation in the spleen after intravenous injection in mice. This approach demonstrates the potential of polyampholyte-based nanovesicles (TPBV) for targeted drug delivery applications to the spleen.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.